Technical Trend Overview and Price Movement
Concord Biotech’s technical trend has transitioned from a bullish stance to a mildly bullish one, signalling a moderation in upward momentum. The stock closed at ₹1,452.60 on 11 Sep 2026, down 0.83% from the previous close of ₹1,464.80. Intraday volatility was evident with a high of ₹1,473.70 and a low of ₹1,431.70, indicating some selling pressure despite attempts to push prices higher.
Over the past 52 weeks, the stock has traded between ₹987.05 and ₹1,702.10, currently sitting closer to the upper end of this range but still below its peak, suggesting room for recovery or consolidation depending on broader market cues.
MACD and Momentum Indicators
The Moving Average Convergence Divergence (MACD) indicator presents a mixed picture. On the weekly chart, the MACD remains bullish, implying that short-term momentum is still positive and buyers retain some control. However, the monthly MACD has turned mildly bearish, signalling that longer-term momentum is weakening and caution is warranted for investors with a longer horizon.
This divergence between weekly and monthly MACD readings highlights the stock’s current indecision phase, where short-term gains may be offset by longer-term profit-taking or uncertainty.
Relative Strength Index (RSI) and Bollinger Bands
The RSI readings on both weekly and monthly timeframes show no clear signal, hovering in neutral zones without indicating overbought or oversold conditions. This neutrality suggests that the stock is not currently experiencing extreme buying or selling pressure, which aligns with the observed sideways price action.
Bollinger Bands provide further insight: weekly bands remain bullish, indicating that price volatility is contained within an upward trending channel. The monthly Bollinger Bands are mildly bullish, reinforcing the notion of a tentative upward bias but with limited conviction.
Patience pays off here! This Micro Cap from Fertilizers sector has delivered steady gains quarter after quarter. Now proudly part of our Reliable Performers list.
- - New Reliable Performer
- - Steady quarterly gains
- - Fertilizers consistency
Moving Averages and KST Analysis
Daily moving averages for Concord Biotech are bullish, indicating that the short-term price trend remains upward. This is a positive sign for traders looking for momentum plays, as the stock price is likely supported by its recent averages.
Conversely, the Know Sure Thing (KST) indicator on the weekly timeframe is bearish, suggesting that momentum may be slowing down or reversing in the near term. The monthly KST reading is unavailable, which limits a full assessment of longer-term momentum from this indicator.
Volume and Dow Theory Signals
On-Balance Volume (OBV) is mildly bearish on the weekly chart, signalling that volume trends are not strongly supporting price advances. This divergence between price and volume can be a warning sign that the current price levels may not be sustainable without stronger buying interest.
Dow Theory assessments on both weekly and monthly charts show no clear trend, reflecting the stock’s current consolidation phase and lack of definitive directional movement.
Comparative Returns and Market Context
From a returns perspective, Concord Biotech has outperformed the Sensex over several key periods despite recent volatility. The stock posted a 0.29% gain over the past week compared to the Sensex’s 1.64% decline. Over one month, Concord Biotech rose 2.52% while the Sensex fell 4.63%. Year-to-date, the stock has gained 7.96%, significantly outperforming the Sensex’s 12.11% loss.
However, over the last year, the stock has declined 13.04%, underperforming the Sensex’s 8.01% drop. Longer-term returns remain robust, with a three-year gain of 43.28% versus the Sensex’s 12.47%, underscoring the company’s resilience and growth potential in the pharmaceuticals and biotechnology sector.
Mojo Score and Analyst Ratings
MarketsMOJO assigns Concord Biotech a Mojo Score of 50.0, reflecting a Hold rating. This is an upgrade from the previous Sell grade as of 31 July 2026, indicating improved confidence in the stock’s prospects. The small-cap classification highlights the stock’s higher volatility and growth potential, which investors should weigh carefully.
The Hold rating suggests that while the stock shows signs of stabilising technical momentum, it may not yet be ready for aggressive accumulation given mixed signals from key indicators.
Holding Concord Biotech Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Investor Takeaway and Outlook
Concord Biotech’s technical landscape is characterised by a blend of bullish and bearish signals, reflecting a stock in transition. The weekly MACD and daily moving averages provide a foundation for cautious optimism, while monthly MACD and KST indicators urge prudence. Neutral RSI readings and mixed volume trends further complicate the outlook.
Investors should monitor key support levels near ₹1,430 and resistance around ₹1,475 to gauge the next directional move. Given the stock’s recent outperformance relative to the Sensex and its upgraded Mojo Grade, selective accumulation may be warranted for those with a medium-term horizon, but risk-averse investors might prefer to wait for clearer confirmation of trend strength.
Overall, Concord Biotech remains a stock with potential in the pharmaceuticals and biotechnology sector, but the current technical signals counsel a balanced approach amid ongoing market uncertainties.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
